Back to news

MeiraGTx Announces Oral Presentation at ObesityWeek 2026

Globe Newswire•16/11/2026•07:00 ET
2

Key Highlights

  • ➤AAV-BDNF restored metabolic homeostasis for over 14 months in diet-induced obese mice
  • ➤BDNF(+/-) mice showed significant weight stabilization and normalized glucose tolerance
  • ➤Ultra-low unilateral doses produced therapeutic rescue with favorable systemic safety results
  • ➤Treatment reduced aggressive and perseverative chasing without impairing pro-social interactions
  • ➤MeiraGTx presented preclinical obesity findings at ObesityWeek 2026

LONDON and NEW YORK, Nov. 16, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced the Company will have an oral presentation at ObesityWeek, in Washington, DC, at 8:30 am ET at the Gaylord National Resort & Convention Center. Hosted annually by The Obesity Society (TOS), ObesityWeek is a premier international scientific conference focused on the multi-disciplinary science, treatment, and prevention of obesity.

The presentation will be available on the Posters and Publications page of the Company’s website.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in